- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- Fluconazole Tablet, IBREXAFUNGERP, Placebo oral tablet
- Drug
- Lead sponsor
- Scynexis, Inc.
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • San Diego, California • Lake Worth, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced May 21, 2026, 10:11 PM EDT